Drug-eluting stents: long-term safety

Full Text

Abstract

The review concerns the problem of late thromboses of drug-eluting stents and their influence on late prognosis of the patients; presents long-term results of the trial of sirolimus-eluting stents implanted to patients with coronary heart disease; analyses mechanisms of development of late stent thrombosis, data from different meta-analyses and registers comparing long-term outcomes in patients with implanted sirolimus-eluting stents and metallic stents; suggests risk factors of late thromboses of drug-eluting stents; presents original evidence on 3.5-year follow-up of patients with implanted sirolimus-eluting stents and metallic stents.

References

  1. Pfisterer M., Brunner-La Rocca H. P., Buser P. T. et al. BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J. Am. Coll. Cardiol. 2006; 48(12): 2584-2589.
  2. Camenzind E., Steg P. G., Wijns W. A meta-analysis of first generation drug eluting stent programs. Circulation 2007; 115: 1440-1445.
  3. Cutlip D. E., Windecker S., Mehran R. et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115: 2344-2351.
  4. Nakazawa G., Finn A. V., Virmani R. Drug-eluting stent pathology-should we still be cautious? Nat. Clin. Pract. Cardiovasc. Med. 2008; 5 (1): 1-3.
  5. Awata M., Kotani J., Uematsu M. Serial angioscopic evidence of incomplete neointimal coverage after sirolimus-eluting stent implantation: comparison with bare-metal stents. Circulation 2007; 116 (8): 910-916.
  6. Togni M., Rдber L., Cocchia R. et al. Local vascular dysfunction after coronary paclitaxel-eluting stent implantation. Int. J. Cardiol. 2007; 120 (2): 212-220.
  7. Virmani R., Guagliumi G., Farb A. et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004; 109: 701-705.
  8. Nebeker J. R., Virmani R., Bennett C. L. et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J. Am. Coll. Cardiol. 2006; 47 (1): 175-181.
  9. Zhang F., Qian J., Ge J. Very late stent thrombosis in late stent malapposition after sirolimus-eluting stent implantation. Int. Heart J. 2007; 48 (5): 591-596.
  10. Steffel J., Latini R. A., Akhmedov A. Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design. Circulation 2005; 112 (13): 2002-2011.
  11. Stone G. W., Moses J. W., Ellis S. G. et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N. Engl. J. Med. 2007; 356: 998-1008.
  12. Spaulding C., Daemen J., Boersma E. et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N. Engl. J. Med. 2007; 356: 989-997.
  13. Mauri L., Hsieh W. H., Massaro J. M. et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N. Engl. J. Med. 2007; 356: 1020.
  14. Nordmann A. J., Briel M., Bucher H. C. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur. Heart J. 2006; 27 (23): 2784-2814.
  15. Stettler C., Wandel S., Allemann S. et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007; 370 (9591): 937-948.
  16. Daemen J., Ong A. T., Stefanini G. G. et al. Three-year clinical follow-up of the unrestricted use of sirolimus-eluting stents as part of the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. Am. J. Cardiol. 2006; 98 (7): 895-901.
  17. de la Torre-Hernдndez J. M., Alfonso F., Hernдndez F. et al. ESTROFA Study Group. Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpaсol sobre TROmbosis de stents FArmacoactivos). J. Am. Coll. Cardiol. 2008; 51 (10): 986-990.
  18. Tu J. V., Bowen J., Chiu M. et al. Effectiveness and safety of drug-eluting stents in Ontario. N. Engl. J. Med. 2007; 357 (14): 1393-1402.
  19. Jensen L. O., Maeng M., Kaltoft A. et al. Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions. J. Am. Coll. Cardiol. 2007; 50 (5): 463-470.
  20. Lagerqvist B., James S. K., Stenestrand U. et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N. Engl. J. Med. 2007; 356: 1009-1019.
  21. Williams D. O., Abbott J. D., Kip K. E. DEScover Investigators. Outcomes of 6906 patients undergoing percutaneous coronary intervention in the era of drug-eluting stents: report of the DEScover Registry. Circulation 2006; 114 (20): 2154-2162.
  22. Abbott J. D., Voss M. R., Nakamura M. et al. Unrestricted use of drug-eluting stents compared with bare-metal stents in routine clinical practice: findings from the National Heart, Lung, and Blood Institute Dynamic Registry. J. Am. Coll. Cardiol. 2007; 50 (21): 2029-2036.
  23. Mauri L., Silbaugh T. S., Wolf R. E. et al. Long-term clinical outcomes after drug-eluting and bare-metal stenting in massachusetts. Circulation 2008; 118 (18): 1817-1827.
  24. Shishehbor M. H., Goel S. S., Kapadia S. R. et al. Long-term impact of drug-eluting stents versus bare-metal stents on all-cause mortality. J. Am. Coll. Cardiol. 2008; 52: 1041-1048.
  25. Anstrom K. J., Kong D. F., Shaw L. K. et al. Long-term clinical outcomes following coronary stenting. Arch. Intern. Med. 2008; 168: 1647-1655.
  26. Kirtane A. Oral presentation at the American College of Cardiology (ACC) 2008 Scientific Sessions www.theheart.org

Statistics

Views

Abstract: 151

Article Metrics

Metrics Loading ...

Refbacks

  • There are currently no refbacks.

Copyright (c) 2009 Karpov Y.A., Samko A.N., Buza V.V., Karpov Y.A., Samko A.N., Buza V.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:

 

© 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies